MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
MacroGenics will webcast its September 16, 2026 H.C. Wainwright conference presentation and host a 30-day replay for investors online.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MacroGenics (MGNX) announced that President and CEO Eric Risser will present at the H.C. Wainwright 28th Annual Global Investment Conference on Wednesday, September 16, 2026, at 9:30 a.m. ET.
The live webcast and an archived replay, available for 30 days, can be accessed via the Investor Relations “Events & Presentations” page on the company’s website.
Details
News Market Reaction – MGNX
On Sep 10, the first trading day after this news, MGNX closed 3.41% below the previous close. Our momentum scanner recorded 8 alerts for this stock that day.
Data tracked by StockTitan Argus for the Sep 10 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKVILLE, MD, Sept. 09, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will present at the H.C. Wainwright 28th Annual Global Investment Conference on Wednesday, September 16, 2026, at 9:30 a.m. ET.
A webcast of the presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain an archived replay of the webcasts on its website for 30 days.
About MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused on developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics, the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.
Contacts: Jim Karrels, Senior Vice President, CFO 1-301-251-5172 info@macrogenics.com Argot Partners 1-212-600-1902 macrogenics@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How can investors access MacroGenics' presentation at the H.C. Wainwright conference?
The live webcast may be accessed under “Events & Presentations” in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm.
Will a replay of the MacroGenics conference presentation be available?
Yes. The company will maintain an archived replay of the webcast on its website for 30 days.
When is MacroGenics scheduled to present at the H.C. Wainwright 28th Annual Global Investment Conference?
Eric Risser, President and CEO of MacroGenics, is scheduled to present on Wednesday, September 16, 2026, at 9:30 a.m. ET.